Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 1
2003 1
2004 1
2005 1
2006 5
2007 9
2008 11
2009 8
2010 9
2011 10
2012 10
2013 10
2014 6
2015 6
2016 3
2017 6
2018 1
2019 1
2020 5
2021 2
2022 10
2023 9
2024 14
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S; ARTEMIS-UC Study Group. Sands BE, et al. N Engl J Med. 2024 Sep 26;391(12):1119-1129. doi: 10.1056/NEJMoa2314076. N Engl J Med. 2024. PMID: 39321363 Clinical Trial.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése.
Miheller P, Kristóf T, Bor R, Farkas K, Golovics P, Harsányi L, Müller KE, Milassin Á, Palatka K, Schäfer E, Szamosi T, Sarlós P, Molnár T. Miheller P, et al. Orv Hetil. 2024 Mar 12;165(Supplement-1):37-64. doi: 10.1556/650.2024.33050. Print 2024 Mar 12. Orv Hetil. 2024. PMID: 38470491 Hungarian. No abstract available.
A Crohn-betegég terápiás stratégiája.
Farkas K, Székely H, Bacsur P, Bánky B, Élthes ZB, Harsányi L, Müllner KE, Milassin Á, Palatka K, Sarlós P, Szamosi T, Molnár T, Miheller P. Farkas K, et al. Among authors: miheller p. Orv Hetil. 2024 Mar 12;165(Supplement-1):1-36. doi: 10.1556/650.2024.33020. Print 2024 Mar 12. Orv Hetil. 2024. PMID: 38470481 Hungarian. No abstract available.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study.
Farkas B, Limdi JK, Bacsur P, Savarino EV, Bertin L, Sethi-Arora K, Miheller P, Vilmos F, Castiglione F, Bonacci L, Lukas M, Maharshak N, Berman G, Krznaric Ž, Wetwittayakhlang P, Lakatos PL, Seidelin JB, Attauabi M, Michalopoulos G, Ribaldone DG, Kagramanova A, Chashkova E, Sarlós P, Saibeni S, Shitrit AB, Borsos M, Resál T, Szepes Z, Molnár T, Farkas K. Farkas B, et al. Among authors: miheller p. Expert Opin Biol Ther. 2025 Jun;25(6):669-678. doi: 10.1080/14712598.2025.2500962. Epub 2025 May 11. Expert Opin Biol Ther. 2025. PMID: 40346848 Free article.
End-to-end anastomosis provides similar quality-of-life, compared with other reconstructive techniques six months following total mesorectal excision: Systematic review and meta-analysis.
Kávási SB, Iov DE, Rancz A, Zolcsák Á, Veres DS, Lenti K, Miheller P, Hegyi P, Ábrahám S. Kávási SB, et al. Among authors: miheller p. Eur J Surg Oncol. 2024 Oct;50(10):108599. doi: 10.1016/j.ejso.2024.108599. Epub 2024 Aug 10. Eur J Surg Oncol. 2024. PMID: 39154431 Free article.
130 results